Skip to main content
Premium Trial:

Request an Annual Quote

International Therapeutics Licenses RNAi Quantification Product to Rosetta

NEW YORK, Sept. 28 (GenomeWeb News) - International Therapeutics has granted to Rosetta Inpharmatics a worldwide nonexclusive license to its ProxiQuant technology for research and development applications, IT said today.

 

ProxiQuant is an enzymatic application that enables stoichiometric generation of surrogate DNA targets from primary RNAi molecules in biological samples, IT said. As opposed to RT-PCR, ProxiQuant uses ligases to create larger DNA molecules from smaller RNAi, which can then be quantified using several methods.

 

Financial details of the agreement were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.